Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa (PiperTazo)
Efficacy and Safety of Piperacillin-Tazobactam Continuous Infusion vs Intermittent Infusion for Complicated or Nosocomial Pseudomonas Aeruginosa Infection or Suspected Infection
Sponsor: Complejo Hospitalario de Especialidades Juan Ramón Jimenez
A PHASE3 clinical study on Pseudomonas Aeruginosa Infection, this trial is completed. The trial is conducted by Complejo Hospitalario de Especialidades Juan Ramón Jimenez and has accumulated 6 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Complejo Hospitalario de Especialidades Juan Ramón Jimenez
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Hospital General de Cataluña
- Hospital Infanta Sofia
- Hospital Son Espases
- Hospital Son Llatzer
- Hospital Universitario Ntra. Sra. de La Candelaria
- Hospital Universitario Virgen Macarena
- Hospitales Universitarios Virgen del Rocío
- Ministerio de Sanidad y Política social
- University Hospital Virgen de las Nieves
For direct contact, visit the study record on ClinicalTrials.gov .